=KalVista Pharmaceuticals (KALV) : Phase 2 clinical trial in diabetic macular edema

KalVista Pharmaceuticals announced results of the Phase 2 clinical trial evaluating the use of KVD001 in patients with diabetic macular edema
The KVD001 Phase 2 clinical trial study was designed to evaluate patients who were poor responders to previous treatment with anti-VEGF therapy. The primary efficacy endpoint in the trial was change in best corrected visual acuity (BCVA) at 16 weeks compared to sham. The 6g dose showed a difference of +2.6 letters versus sham, which was not statistically significant, and the 3g dose showed a difference of +1.5 letters. No significant differences were observed in the secondary endpoints of central subfield thickness (CST) or the diabetic retinopathy severity scale (DRSS). KVD001 was generally safe and well tolerated with no drug-related serious adverse events.